

Policy Implications: Addressing Substance Use Disorder as a Matter of Public Health


Whitney Englander Government Relations Manager 626-808-6923 <u>englander@harmreduction.org</u> www.harmreduction.org

"As someone who has spent their entire career in law enforcement, I know we cannot arrest our way out of the drug problem."

Former Director Kerlikowske, Executive Office of the Presidency, United States Office of National Drug Control Policy

Substance Use Disorder is a brain disease

- -Chronic, relapsing brain disease
- -Relapse rates similar to other chronic illnesses such as asthma, diabetes and heart disease.
- -Developmental disease typically beginning in childhood



Source: The Journal of Neuroscience, 21(23):9414-9418. 2001 COMPARISON OF RELAPSE RATES BETWEEN DRUG ADDICTION AND OTHER CHRONIC ILLNESSES

Percentage of Patients Who Relapse

TYPE I DIABETES



DRUG ADDICTION

ули селектика селектрические 40 то 60%


HYPERTENBION

50 TO 70%

ASTHMA

Source: National Institutes for Health, National Institute on Drug Abuse: http://www.drugabuse.gov/publications/science-addiction/drug-abuse-addiction

50 TO 70%



STAGE OF TREATMENT

Source: National Institutes for Health, National Institute on Drug Abuse: http://www.drugabuse.gov/publications/science-addiction/drug-abuseaddiction

Cost-Effectiveness of Treatment



Source: National Institutes for Health, National Institute on Drug Abuse: http://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guidethird-edition/frequently-asked-questions/drug-addiction-treatment-worth-its-cost

Supply Side

- Prescription Drug Monitoring Programs
- Drug Disposal
- Prescribing guidelines
- Traditional interdiction efforts

Demand Reduction Strategies

- Overdose prevention and education
- Treatment Access
- Medication Assisted Treatment access & reform
- Primary prevention

Changing Landscape

- 2008 Recession
- Prescription Drug Epidemic
- Change of Demographics
- Bi-partisan
- New Stakeholders
- Affordable Care Act
- Parity Implementation




"Drug overdose death rates in the United States have never been higher"


Source: Unintentional Drug Poisoning in the United States – CDC Issue Brief – March 19, 2010

Source: http://www.cdc.gov/HomeandRecreationalSafet y/pdf/poison-issue-brief.pdf

Figure 1: Rate of unintentional drug overdose death in the United States, 1970-2007



Source: National Vital Statistics System



Source: National Vital Statistics System


Overdose in the U.S.

- More than 24,000 deaths from opioids in 2013
- Non-heroin opioid treatment admissions up 345%

Center for Disease Control and Prevention 2013 Mortality data http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_02.pdf

Warner, et. Al. 2011 http://www.cdc.gov/nchs/data/databriefs/db81.pdf

Naloxone (Narcan)



Graphics: Maya Doe-Simkins

Overdose Prevention Education & Naloxone Distribution

Prescribed opioid antagonist which rapidly reverses opioid related sedation and respiratory depression and may cause withdrawal

Naloxone access may be expanded in two major ways:

- 1- Community and public agency programming (distribution model)
- 2- Integration into healthcare delivery system (coprescription)

Overdose prevention programs: US

- As of 2010, there were 48 known programs, representing 188 community-based sites in 15 states and DC.
- 53,032 individuals have been trained in naloxone administration and overdose response
- 10,171 overdose reversals reported

CDC MMWR February 17, 2012 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6106a1.htm Survey completed by Eliza Wheeler <u>wheeler@harmreduction.org</u>

Legal issues

- All state laws allow for prescription of naloxone by a physician to those at risk of overdose
- Some states have passed legislation to allow for prescribing to *anyone* potentially at risk of witnessing an overdose (including family, friends or service providers)
- Other jurisdictions have passed local laws or initiated pilot programs

2013 State Legislative Action

Legislation expanding naloxone passed:


• Colorado, District of Columbia, Kentucky, Maryland, New Jersey, North Carolina, Oklahoma, Oregon, Vermont, and Virginia.


Legislation to expand naloxone pending:


• California, Connecticut, Illinois, Massachusetts, New Mexico, New York Ohio, and West Virginia.

Good Samaritan legislation introduced/enacted:

• Massachusetts, Mississippi, Missouri, and New Jersey.








In Conclusion

120 Americans are lost everyday to overdose, an epidemic with mortality rates similar to the peak of the HIV/AIDS epidemic.



Acknowledgements

- Dr. Sharon Stancliff, MD
- Eliza Wheeler, MA
- Corey Davis, JD

American Society of Addiction Medicine Report: -Reimbursement and coverage discrimination (medication and counseling) -Few treatment providers Structural discrimination and stigma Cultural resistance to treating addiction as a disease with medical interventions Poor referral networks